Mylan Launches Generic Epivir-HBV® Tablets

Jan 15, 2015, 14:29 ET from Mylan Inc.

PITTSBURGH, Jan. 15, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's Epivir-HBV®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation.(1)

Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1 million for the 12 months ending September 30, 2014, according to IMS Health.

Currently, Mylan has 284 ANDAs pending FDA approval representing $109.1 billion in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3 billion in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 25,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com.

(1) Use of Lamivudine has been associated with lactic acidosis and fatty liver disease. Acute exacerbations of Hepatitis B have occurred upon discontinuation.  In patients with unrecognized or untreated HIV, resistance may emerge while treating Hepatitis B with Lamivudine.

 

SOURCE Mylan Inc.



RELATED LINKS

http://www.mylan.com